Acetamide, 2-[(6-chloro-3-pyridazinyl)oxy]-N-[1-[(2,2-difluorocyclopropyl)methyl]-4-piperidinyl]-N-methyl- manufacturers
- FGFR-IN-7
-
- $1520.00
-
2026-07-27
- CAS:2488764-17-4
- Purity:
- Supply Ability: 10g
|
| | Acetamide, 2-[(6-chloro-3-pyridazinyl)oxy]-N-[1-[(2,2-difluorocyclopropyl)methyl]-4-piperidinyl]-N-methyl- Basic information |
| | Acetamide, 2-[(6-chloro-3-pyridazinyl)oxy]-N-[1-[(2,2-difluorocyclopropyl)methyl]-4-piperidinyl]-N-methyl- Chemical Properties |
| Boiling point | 540.1±50.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | pka | 8.94±0.20(Predicted) |
| | Acetamide, 2-[(6-chloro-3-pyridazinyl)oxy]-N-[1-[(2,2-difluorocyclopropyl)methyl]-4-piperidinyl]-N-methyl- Usage And Synthesis |
| Uses | FGFR-IN-7 (compound 17) is an orally active, potent and BBB-penetrated FGFR (fibroblast growth factor receptor) modulator. FGFR-IN-7 shows neuroprotective activity. FGFR-IN-7 improves brain exposure and reduced risk of phospholidosis. FGFR-IN-7 can be used for neurodegenerative diseases research[1]. | | in vivo | FGFR-IN-7 (compound 17) (1 mg/kg, Orally, once daily for 10 days) significantly enhances recovery of coordinated movement in the in vivo rat acute stroke model[1]. | | References | [1] Sakai H, et al. Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential. Bioorg Med Chem. 2020 Jul 15;28(14):115562. DOI:10.1016/j.bmc.2020.115562 |
| | Acetamide, 2-[(6-chloro-3-pyridazinyl)oxy]-N-[1-[(2,2-difluorocyclopropyl)methyl]-4-piperidinyl]-N-methyl- Preparation Products And Raw materials |
|